These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38541766)

  • 1. Δ
    Pressman P; Hayes AW; Hoeng J; Latino DARS; Mazurov A; Schlage WK; Rana A
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
    Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
    JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.
    Jacobs DS; Kohut SJ; Jiang S; Nikas SP; Makriyannis A; Bergman J
    Exp Clin Psychopharmacol; 2016 Oct; 24(5):320-330. PubMed ID: 27690502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blunting of the HPA-axis underlies the lack of preventive efficacy of early post-stressor single-dose Delta-9-tetrahydrocannabinol (THC).
    Mayer TA; Matar MA; Kaplan Z; Zohar J; Cohen H
    Pharmacol Biochem Behav; 2014 Jul; 122():307-18. PubMed ID: 24814135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance.
    Müller-Vahl KR; Koblenz A; Jöbges M; Kolbe H; Emrich HM; Schneider U
    Pharmacopsychiatry; 2001 Jan; 34(1):19-24. PubMed ID: 11229617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a Delta-9-Tetrahydrocannabinol Carboxylic Acid (Δ9-THC-COOH) Immunoassay and a Gas Chromatography-Mass Spectrometry (GC-MS) Method for the Detection of Delta-8-Tetrahydrocannabinol Carboxylic Acid (Δ8-THC-COOH).
    Baird SN; Frazee CC; Garg U
    J Appl Lab Med; 2023 Jul; 8(4):665-673. PubMed ID: 37071885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacology of Delta9-tetrahydrocannabinol and its metabolite, 11-OH-Delta9-tetrahydrocannabinol.
    Lemberger L; Martz R; Rodda B; Forney R; Rowe H
    J Clin Invest; 1973 Oct; 52(10):2411-7. PubMed ID: 4729039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes.
    Brenneisen R; Meyer P; Chtioui H; Saugy M; Kamber M
    Anal Bioanal Chem; 2010 Apr; 396(7):2493-502. PubMed ID: 20112012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
    Roser P; Juckel G; Rentzsch J; Nadulski T; Gallinat J; Stadelmann AM
    Eur Neuropsychopharmacol; 2008 Aug; 18(8):569-77. PubMed ID: 18544469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva).
    Darmani NA; Crim JL
    Pharmacol Biochem Behav; 2005 Jan; 80(1):35-44. PubMed ID: 15652378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Δ9-tetrahydrocannabinol and its major metabolite Δ9-tetrahydrocannabinol-11-oic acid as 15-lipoxygenase inhibitors.
    Takeda S; Jiang R; Aramaki H; Imoto M; Toda A; Eyanagi R; Amamoto T; Yamamoto I; Watanabe K
    J Pharm Sci; 2011 Mar; 100(3):1206-11. PubMed ID: 20891010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occupational Exposure to Secondhand Cannabis Smoke Among Law Enforcement Officers Providing Security at Outdoor Concert Events.
    Wiegand DM; Methner MM; Grimes GR; Couch JR; Wang L; Zhang L; Blount BC
    Ann Work Expo Health; 2020 Aug; 64(7):705-714. PubMed ID: 32219297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.
    Müller-Vahl KR; Schneider U; Koblenz A; Jöbges M; Kolbe H; Daldrup T; Emrich HM
    Pharmacopsychiatry; 2002 Mar; 35(2):57-61. PubMed ID: 11951146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
    Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
    Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta9-tetrahydrocannabinol.
    Williams IJ; Edwards S; Rubo A; Haller VL; Stevens DL; Welch SP
    Eur J Pharmacol; 2006 Jun; 539(1-2):57-63. PubMed ID: 16687136
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.